<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01530841</url>
  </required_header>
  <id_info>
    <org_study_id>2010-A01306-33</org_study_id>
    <nct_id>NCT01530841</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerance of AVAPS Mode in Myotonic Dystrophy</brief_title>
  <official_title>Prospective Randomized Controlled Single Blind Study of Efficacy and Tolerance of AVAPS Mode Compared to Bilevel Pressure Ventilation un Adult Patients With Myotonic Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre d'Investigation Clinique et Technologique 805</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adep Assistance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Philips Respironics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre d'Investigation Clinique et Technologique 805</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myotonic dystrophy type 1 is a myopathy with complex respiratory pattern and at risk to&#xD;
      develop respiratory failure. Classical mode of ventilation are sometimes not tolerated or&#xD;
      ineffective in this population. New modes of nocturnal ventilation by combining both&#xD;
      volumetric and barometric advantages. The aim of this study is to compare effect of AVAPS&#xD;
      mode to bilevel pressure support.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Justification of study&#xD;
&#xD;
      Respiratory abnormalities are complex in Myotonic dystrophy type 1. Some patients presented&#xD;
      with isolated alveolar hypoventilation and breathe rhythm irregularity. Nocturnal ventilation&#xD;
      is usually proposed but usual modes of ventilation can't provide enough respiratory&#xD;
      assistance for patients especially during REM sleep or too much respiratory assistance&#xD;
      increasing the risk of asynchrony. The goal of this study is to evaluate the effect of the&#xD;
      mode AVAPS (a mode permitting a pressure support with guaranteed volume and offering&#xD;
      advantage of volume and pressure support with Bipap A30 Phillips Respironics) compared to&#xD;
      bilevel pressure support.&#xD;
&#xD;
      Main Objective To evaluate efficacy of AVAPS Mode at day 7 on arterial PCO2 under ventilation&#xD;
      after launching ventilation.&#xD;
&#xD;
      Secondary Objectives To evaluate efficacy of AVAPS Mode at day 90 on daytime arterial PCO2&#xD;
      after launching ventilation.&#xD;
&#xD;
      To evaluate compliance to ventilation at day 7 and 90. To evaluate clinical efficacy on&#xD;
      respiratory symptoms, dyspnea and sleepiness at day 1 and 90.&#xD;
&#xD;
      To evaluate quality of life at day 1 and 90. To evaluate effect of AVAPS on polysomnography,&#xD;
      nocturnal SaO2, nocturnal PtCO2.&#xD;
&#xD;
      To evaluate Multiple sleep latency and Maintenance of wakefulness tests at day 90.&#xD;
&#xD;
      To evaluate effect of AVAPS on respiratory parameters VC and mouth maximal pressures.&#xD;
&#xD;
      Type of study: Prospective, monocentre, randomized, controlled single blind study on 2&#xD;
      parallel group.&#xD;
&#xD;
      Number of subjects: 32 patients recruited in home ventilation unit of Raymond Poincaré&#xD;
      hospital.&#xD;
&#xD;
      Selection criteria : Patients with Myotonic dystrophy presenting at least one clinical signs&#xD;
      : effort or rest dyspnea, orthopnea, sleepiness, morning headache or VC&lt;50% or Pi max&lt; 60 cm&#xD;
      H2O or time of SaO2&lt;90% more than 5 minutes and Hypercapnia &gt; 6.0 kPa.&#xD;
&#xD;
      Study process Preceding screening period within the 3 months before inclusion. Day 1 to day 3&#xD;
      baseline evaluation. Day 3 Inclusion and Randomisation Day 3 to 8 Launch of ventilation Day 8&#xD;
      Home discharge Day 90 Evaluation of efficacy (secondary objectives) and observance.&#xD;
&#xD;
      Duration Participation of a patient 3 months. Period of inclusion 24 months. Total duration&#xD;
      of study 30 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>arterial PCO2 under ventilation</measure>
    <time_frame>7 days</time_frame>
    <description>To evaluate efficacy of AVAPS Mode versus bilevel pressure mode at day 7 on arterial PCO2 under ventilation after launching ventilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>daytime arterial PCO2 after launching ventilation.</measure>
    <time_frame>90 days</time_frame>
    <description>To evaluate efficacy of AVAPS Mode at day 90 on daytime arterial PCO2 after launching ventilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance to ventilation</measure>
    <time_frame>7 and 90 days</time_frame>
    <description>To evaluate compliance (h/24h) to ventilation at days 7 and 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms</measure>
    <time_frame>90 days</time_frame>
    <description>To evaluate clinical efficacy on respiratory symptoms, dyspnea and sleepiness at day 1 and 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep studies</measure>
    <time_frame>90 days</time_frame>
    <description>To evaluate effect of AVAPS on polysomnography, nocturnal SaO2, nocturnal PtCO2 at day 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OBJECTIVE SLEEPINESS</measure>
    <time_frame>90 days</time_frame>
    <description>To evaluate Multiple sleep latency and Maintenance of wakefulness tests at day 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory parameters</measure>
    <time_frame>90 days</time_frame>
    <description>To evaluate effect of AVAPS on respiratory parameters VC and mouth maximal pressures.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Myopathy</condition>
  <arm_group>
    <arm_group_label>AVAPS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm assigned to AVAPS mode for nocturnal ventilation with the same setting than bilevel pressure support but with AVAPS mode activated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bilevel pressure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm treated only with bilevel pressure support for nocturnal ventilation without activation of AVAPS mode</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nocturnal ventilation</intervention_name>
    <description>Home ventilation only the mode AVAPS will be used if the patient is randomized in the experimental group.</description>
    <arm_group_label>AVAPS</arm_group_label>
    <arm_group_label>Bilevel pressure</arm_group_label>
    <other_name>BIPAP A30</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women aged &gt; 18 years&#xD;
&#xD;
          -  Written consent&#xD;
&#xD;
          -  DM1 myotonic dystrophy&#xD;
&#xD;
          -  One clinical signs dyspnea rest/effort, orthopnea, daytime sleepiness (Epworth&gt; 10),&#xD;
             morning headache.&#xD;
&#xD;
        Or restrictive syndrome: VC&lt; 50 % or Pi max &lt;60 cm H2O Or time of nocturnal saturation &lt; 90&#xD;
        %, &gt; 5 minutes. AND Hypercapnia &gt; 6.0 kPa Pregnancy test negative or use of contraception&#xD;
        for women in age of procreation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient using previously home ventilation within the 6 months before entering the&#xD;
             study&#xD;
&#xD;
          -  Patient denying home ventilation&#xD;
&#xD;
          -  Refusal to sign consent&#xD;
&#xD;
          -  impossibility to be followed during 3 months&#xD;
&#xD;
          -  Impossibility to apply ventilation at home&#xD;
&#xD;
          -  No social/health coverage&#xD;
&#xD;
          -  Patient under tutelage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David ORLIKOWSKI, Md-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Raymond Poincare Hospital - Garches - France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Home ventilation Unit , Raymond Poincaré hospital</name>
      <address>
        <city>Garches</city>
        <state>Paris Area</state>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>February 8, 2012</study_first_submitted>
  <study_first_submitted_qc>February 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2012</study_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre d'Investigation Clinique et Technologique 805</investigator_affiliation>
    <investigator_full_name>david orlikowski</investigator_full_name>
    <investigator_title>Professor, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Myotonic dystrophy type 1</keyword>
  <keyword>Home ventilation</keyword>
  <keyword>Respiratory insufficiency</keyword>
  <keyword>Neuromuscular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myotonic Dystrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

